Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Am J Hematol. 2017 Jun 1;92(8):759–763. doi: 10.1002/ajh.24762

Table 3.

Clinical response1

Efficacy n, (%)
ORR 12 (92%)
CR/CRi 5 (38%)
CCR 1 (7.7%)
nPR 1 (7.7%)
PR 5 (38%)
PD 1 (7.7%)
1

Response was evaluated two months after the last cycle of therapy per IWCLL 2008 criteria.[15]